Polypharmacy in Treatment of Behavioral Issues in Dementia—Use of Atypical Antipsychotics

Published:September 11, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cloak N.
        • Al Khalili Y.
        Behavioral and psychological symptoms in dementia.
        in: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)2022 (Accessed December 20, 2021)
        • Leelakanok N.
        • Holcombe A.L.
        • Lund B.C.
        • et al.
        Association between polypharmacy and death: a systematic review and meta-analysis.
        J Am Pharm Assoc (2003). 2017; 57: 729-738.e10
        • Lai S.W.
        • Liao K.F.
        • Liao C.C.
        • et al.
        Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study.
        Medicine (Baltimore). 2010; 89: 295-299
        • Maust D.T.
        • Strominger J.
        • Kim H.M.
        • et al.
        Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US.
        JAMA. 2021; 325: 952-961
        • Lau D.T.
        • Mercaldo N.D.
        • Harris A.T.
        • et al.
        Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia.
        Alzheimer Dis Assoc Disord. 2010; 24: 56-63
        • Fried T.R.
        • O'Leary J.
        • Towle V.
        • et al.
        Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.
        J Am Geriatr Soc. 2014; 62: 2261-2272
        • Tible O.P.
        • Riese F.
        • Savaskan E.
        • et al.
        Best practice in the management of behavioural and psychological symptoms of dementia.
        Ther Adv Neurol Disord. 2017; 10: 297-309
        • Thompson Coon J.
        • Abbott R.
        • Rogers M.
        • et al.
        Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review.
        J Am Med Dir Assoc. 2014; 15: 706-718
        • Ngo J.
        • Holroyd-Leduc J.M.
        Systematic review of recent dementia practice guidelines.
        Age Ageing. 2015; 44: 25-33
        • Reus V.I.
        • Fochtmann L.J.
        • Eyler A.E.
        • et al.
        The American psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.
        Am J Psychiatry. 2016; 173: 543-546
        • National Institute for Health and Care Excellence (NICE)
        Dementia: assessment, management and support for people living with dementia and their carers.
        (Available at:) (Accessed January 14, 2021)
        • Moore A.
        • Patterson C.
        • Lee L.
        • et al.
        Canadian consensus conference on the diagnosis and treatment of dementia. fourth canadian consensus conference on the diagnosis and treatment of dementia: recommendations for family physicians.
        Can Fam Physician. 2014; 60: 433-438
        • Laver K.
        • Cumming R.G.
        • Dyer S.M.
        • et al.
        Clinical practice guidelines for dementia in Australia.
        Med J Aust. 2016; 204: 191-193
        • Harrison S.L.
        • Cations M.
        • Jessop T.
        • et al.
        Approaches to deprescribing psychotropic medications for changed behaviours in long-term care residents living with dementia.
        Drugs Aging. 2019; 36: 125-136
        • Tampi R.R.
        • Tampi D.J.
        • Rogers K.
        • et al.
        Antipsychotics in the management of behavioral and psychological symptoms of dementia: maximizing gain and minimizing harm.
        Neurodegener Dis Manag. 2020; 10: 5-8
        • Bessey L.J.
        • Walaszek A.
        Management of behavioral and psychological symptoms of dementia.
        Curr Psychiatry Rep. 2019; 21 (Published 2019 Jul 1): 66
        • Terman L.A.
        Treatment of senile agitation with chlorpromazine.
        Geriatrics. 1955; 10: 520-522
        • Yunusa I.
        • El Helou M.L.
        The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use.
        Front Pharmacol. 2020; 11 (Published 2020 May 20): 596
        • Caraci F.
        • Santagati M.
        • Caruso G.
        • et al.
        New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
        F1000Res. 2020; 9 (Faculty Rev-686): F1000
        • Maglione M.
        • Ruelaz Maher A.
        • Hu J.
        • et al.
        Off-label use of atypical antipsychotics: an update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062- 1.).
        Agency for Healthcare Research and Quality, Rockville, MD2011 (Available at:)
        • Bjerre L.M.
        • Farrell B.
        • Hogel M.
        • et al.
        Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline.
        Can Fam Physician. 2018; 64: 17-27
        • Ravona-Springer R.
        • Davidson M.
        Considerations in psychotropic treatments in dementia--can polypharmacy be avoided?.
        Int J Neuropsychopharmacol. 2014; 17: 1107-1117
        • Schneider L.S.
        • Tariot P.N.
        • Dagerman K.S.
        • et al.
        Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
        N Engl J Med. 2006; 355: 1525-1538
        • Tampi R.R.
        • Tampi D.J.
        • Balachandran S.
        • et al.
        Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.
        Ther Adv Chronic Dis. 2016; 7: 229-245
        • Yunusa I.
        • Alsumali A.
        • Garba A.E.
        • et al.
        Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis.
        JAMA Netw Open. 2019; 2 (Published 2019 Mar 1): e190828
        • Mathys M.
        Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder.
        Ment Health Clin. 2018; 8 (Published 2018 Nov 1): 284-293
        • Nagata T.
        • Shinagawa S.
        • Yoshida K.
        • et al.
        Early improvements of individual symptoms with antipsychotics predict subsequent treatment response of neuropsychiatric symptoms in alzheimer's disease: a re-analysis of the CATIE-AD study.
        J Clin Psychiatry. 2020; 81 (Published 2020 Feb 11): 19m12961
        • US Food and Drug Administration
        Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances.
        (Available at:) (Accessed December 10, 2021)
        • US Food and Drug Administration
        Information for healthcare professionals: conventional antipsychotics.
        (Available at:) (Accessed December 10, 2021)
        • Ballard C.
        • Hanney M.L.
        • Theodoulou M.
        • et al.
        The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
        Lancet Neurol. 2009; 8: 151-157
        • Tjia J.
        • Reidenberg M.M.
        • Hunnicutt J.N.
        • et al.
        Approaches to gradual dose reduction of chronic off-label antipsychotics used for behavioral and psychological symptoms of dementia.
        Consult Pharm. 2015; 30: 599-611
        • Berman B.D.
        Neuroleptic malignant syndrome: a review for neurohospitalists.
        Neurohospitalist. 2011; 1: 41-47
        • Berardi D.
        • Amore M.
        • Keck P.E.
        • et al.
        Clinical and pharmacological risk factors for neuroleptic malignant syndrome : a case control study.
        Biol Psychiatry. 1998; 44: 748-754
        • Bhanushali M.J.
        • Tuite P.J.
        The evaluation and management of patients with neuroleptic malignant syndrome.
        Neurol Clin. 2004; 22: 389-411
        • Keck P.E.
        • Pope H.G.
        • Cohen B.M.
        • et al.
        Risk factors for neuroleptic malignant syndrome: a case-control study.
        Arch Gen Psychiatry. 1989; 46: 914-918
        • Porsteinsson A.P.
        • Drye L.T.
        • Pollock B.G.
        • et al.
        Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
        JAMA. 2014; 311: 682-691
        • Ho T.
        • Pollock B.G.
        • Mulsant B.H.
        • et al.
        R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
        Br J Clin Pharmacol. 2016; 82: 784-792
        • Farina N.
        • Morrell L.
        • Banerjee S.
        What is the therapeutic value of antidepressants in dementia? A narrative review.
        Int J Geriatr Psychiatry. 2017; 32: 32-49
        • Kales H.C.
        • Lyketsos C.G.
        • Miller E.M.
        • et al.
        Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus.
        Int Psychogeriatr. 2019; 31: 83-90
        • Orsel K.
        • Taipale H.
        • Tolppanen A.M.
        • et al.
        Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease.
        Eur Neuropsychopharmacol. 2018; 28: 1260-1269
        • Van Leeuwen E.
        • Petrovic M.
        • van Driel M.L.
        • et al.
        Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia [published online ahead of print, 2018 Mar 30].
        Cochrane Database Syst Rev. 2018; 3: CD007726
        • Ruths S.
        • Straand J.
        • Nygaard H.A.
        • et al.
        Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).
        Int J Geriatr Psychiatry. 2008; 23: 889-895
        • Brodaty H.
        • Aerts L.
        • Harrison F.
        • et al.
        Antipsychotic deprescription for older adults in long-term care: the HALT study.
        J Am Med Dir Assoc. 2018; 19: 592-600.e7
        (Available at:) (Accessed January 15, 2022)
        • Bravo-José P.
        • Sáez-Lleó C.I.
        • Peris-Martí J.F.
        Deprescribing antipsychotics in long term care patients with dementia. Deprescribing antipsychotics in long term care patients with dementia.
        Farm Hosp. 2019; 43 (Published 2019 Jul 1): 140-145